Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

6.430 +0.160 (+2.55%)
Streaming Delayed Price Updated: 12:19 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 145,719
Open 6.250
Bid (Size) 6.410 (10)
Ask (Size) 6.430 (7)
Prev. Close 6.270
Today's Range 6.100 - 6.500
52wk Range 5.010 - 12.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns. 
Via Benzinga

Performance

YTD
-28.48%
-28.48%
1 Month
-10.94%
-10.94%
3 Month
-11.55%
-11.55%
6 Month
-23.63%
-23.63%
1 Year
+5.41%
+5.41%

More News

Read More
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
Via Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
Via Talk Markets
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Via Benzinga
Exposures Product Safety
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
Via Talk Markets
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
Should You Buy the Dip on Compass Pathways Stock?
Via The Motley Fool
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Via The Motley Fool
Exposures Product Safety
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What's Going On With MindMed And Psychedelic Stocks?
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.